The shortcomings of clinical trials assessing the efficacy of probiotics in irritable bowel syndrome

Journal of Alternative and Complementary Medicine

Volumn 18, Issue 2, 2012, Pages 112-119

  Rogers, Nathan J ^a   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; PLACEBO; PROBIOTIC AGENT; TEGASEROD;

BIFIDOBACTERIUM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; LACTOBACILLUS; MEDLINE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

BACTERIA; CLINICAL TRIALS AS TOPIC; HUMANS; IRRITABLE BOWEL SYNDROME; PLACEBO EFFECT; PROBIOTICS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84857465923     PISSN: 10755535     EISSN: 15577708     Source Type: Journal    
DOI: 10.1089/acm.2011.0015     Document Type: Review

References (57)

1. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lacto-bacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001;13:1143-1147. (Pubitemid 33015878)
2. Bommelaer G, et al. Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. Gastroenterol Clin Biol 2004;28(6-7 pt 1): 554-561. (Pubitemid 38917487)
3. Rey E, Talley NJ. Irritable bowel syndrome: Novel views on the epidemiology and potential risk factors. Dig Liver Dis 2009;41:772-780.
4. Brandt LJ, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastro-enterol 2002;97(11 suppl):S7-S26.
5. Guyonnet D, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: A multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007; 26:475-486. (Pubitemid 47063138)
6. Di Piro JT, et al. Pharmacotherapy: A Pathophysiologic Approach, 7th ed. New York: McGraw-Hill Companies, 2008.
7. Barbara G, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126:693-702. (Pubitemid 38298317)
8. Rousseaux C, et al. Lactobacillus acidophilus modulates in-testinal pain and induces opioid and cannabinoid receptors. Nat Med 2007;13:35-37 (Pubitemid 46067383)
9. Balsari A, et al. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982;5:185-194. (Pubitemid 13228114)
10. Si JM, et al. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004;10:1802-1805.
11. Malinen E, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100:373-382. (Pubitemid 40314522)
12. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998;352:1187-1189. (Pubitemid 28458534)
13. Johansson ML, et al. Administration of different Lactoba-cillus strains in fermented oatmeal soup: In vivo colonization of human intestinal mucosa and effect on the indigenous flora. Appl Environ Microbiol 1993;59:15-20.
14. O'Mahony L, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and rela-tionship to cytokine profiles. Gastroenterology 2005;128: 541-551. (Pubitemid 40585355)
15. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003; 124:1662-1671. (Pubitemid 36617684)
16. Tornblom H, et al. Full-thickness biopsy of the jejunum re-veals inflammation and enteric neuropathy in irritable bo-wel syndrome. Gastroenterology 2002; 123:1972-1979. (Pubitemid 35408321)
17. Chadwick VS, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778-1783. (Pubitemid 34651421)
18. Ligaarden SC, et al. A candidate probiotic with unfavour-able effects in subjects with irritable bowel syndrome: A randomised controlled trial. BMC Gastroenterol 2010;10:16.
19. Drouault-Holowacz S, et al. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol 2008; 32:147-152. (Pubitemid 351637577)
20. Patel SM, et al. The placebo effect in irritable bowel syn-drome trials: A meta-analysis. Neurogastroenterol Motil 2005;17:332-340. (Pubitemid 40768905)
21. Pitz M, Cheang M, Bernstein CN. Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3: 237-247. (Pubitemid 40568729)
22. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome: A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000;32: 294-301. (Pubitemid 30445067)
23. Whorwell PJ, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bo-wel syndrome. Am J Gastroenterol 2006;101:1581-1590. (Pubitemid 43980633)
24. Chang JY, Talley NJ. Current and emerging therapies in ir-ritable bowel syndrome: From pathophysiology to treat-ment. Trends Pharmacol Sci 2010; 31:326-334.
25. Brenner DM, et al. The utility of probiotics in the treatment of irritable bowel syndrome: A systematic review. Am J Gastroenterol 2009;104:1033-1049; quiz 1050.
26. Camilleri M. Probiotics and irritable bowel syndrome: Ra-tionale, mechanisms, and efficacy. J Clin Gastroenterol 2008;42(suppl 3 pt 1):S123-S125.
27. Quigley EM. Probiotics in functional gastrointestinal dis-orders: What are the facts? Curr Opin Pharmacol 2008;8: 704-708.
28. Kim HJ, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predom-inant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895-904. (Pubitemid 36459602)
29. Kim HJ, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syn-drome with bloating. Neurogastroenterol Motil 2005;17: 687-696. (Pubitemid 41400717)
30. Nobaek S, et al. Alteration of intestinal microflora is asso-ciated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-1238. (Pubitemid 30263518)
31. Martoni C, et al. Microencapsulated bile salt hydrolase producing Lactobacillus reuteri for oral targeted delivery in the gastrointestinal tract. Appl Microbiol Biotechnol 2008;81: 225-233.
32. Begley M, Hill C, Gahan CG. Bile salt hydrolase activity in probiotics. Appl Environ Microbiol 2006;72:1729-1738.
33. Zeng J, et al. Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoeapredominant irritable bowel syndrome. Aliment Pharmacol Ther 2008;28:994-1002.
34. Kajander K, et al. A probiotic mixture alleviates symp-toms in irritable bowel syndrome patients: A controlled 6-month intervention. Aliment Pharmacol Ther 2005;22: 387-394. (Pubitemid 41248105)
35. Simren M, et al. Clinical trial: The effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome: A randomized, double-blind, controlled study. Aliment Pharmacol Ther 2010;31:218-227
36. Enck P, et al. A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irri-table bowel syndrome: A randomized controlled trial with primary care physicians. Neurogastroenterol Motil 2008;20: 1103-1109.
37. Hong KS, et al. Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome. Gut Liver 2009;3:101-107.
38. Williams EA, Stimpson J, Wang D, et al. Clinical trial: A multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 2009; 29:97-103.
39. Rome Foundation. 2010 [cited November 23, 2010]. Online document at: www.romecriteria.org/criteria/Accessed November 23, 2010.
40. Sinn DH, et al. Therapeutic effect of Lactobacillus acid-ophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008; 53:2714-2718.
41. Dolin BJ. Effects of a proprietary Bacillus coagulans prepa-ration on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol 2009;31:655-659.
42. Gawronska A, et al. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007;25:177-184. (Pubitemid 46046374)
43. Andriulli A, et al. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: A multicenter, randomized study. J Clin Gastroenterol 2008;42(suppl 3 pt 2):S218-S223.
44. Chassany O, et al. Validation of a specific quality of life questionnaire for functional digestive disorders. Gut 1999; 44:527-533. (Pubitemid 29169953)
45. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ 1993;2:217-227.
46. Francis CY, Morris J, Whorwell PJ. The irritable bowel se-verity scoring system: A simple method of monitoring irri-table bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395-402. (Pubitemid 27183522)
47. Heaton KW, et al. Defecation frequency and timing, and stool form in the general population: A prospective study. Gut 1992;33:818-824.
48. Sternbach RA. The effects of instructional sets on autonomic responsivity. Psychophysiology 1964;1:67-72.
49. Lewis JH. Alosetron for severe diarrhea-predominant irri-table bowel syndrome: Safety and efficacy in perspective. Expert Rev Gastroenterol Hepatol 2010;4:13-29.
50. Johnson FR, et al. Quantifying women's stated benefit-risk trade-off preferences for IBS treatment outcomes. Value Health 2010;13:418-423.
51. Loughlin J, et al. Tegaserod and the risk of cardiovascular ischemic events: An observational cohort study. J Cardio-vasc Pharmacol Ther 2010;15:151-157
52. Anderson JL, et al. Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study. J Cardiovasc Pharmacol Ther 2009;14:170-175.
53. Hasler WL, Schoenfeld P. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome. Drug Saf 2004; 27:619-631. (Pubitemid 38980448)
54. Tegaserod Clinical Research Group. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome [in Chinese]. Zhonghua Nei Ke Za Zhi 2003; 42: 88-90.
55. Al-Judaibi B, Chande N, Gregor J. Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation. Can J Clin Pharmacol 2010;17:e194-e200.
56. Busti AJ, Murillo JR Jr, Cryer B. Tegaserod-induced myo-cardial infarction: Case report and hypothesis. Pharma-cotherapy 2004;24:526-531. (Pubitemid 38420542)
57. Smith TJ, Margolis LM, Young AJ. Should military din-ing facilities offer and promote consumption of probiotic-containing foods? Military Med 2010;175:770-783.